---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-009810"
form_type: "8-K"
ticker: "KYTX"
cik: "0001994702"
company_name: "Kyverna Therapeutics, Inc."
filed_at: "2026-01-12T23:59:59+00:00"
generated_at: "2026-05-16T10:58:13.519644+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Kyverna plans BLA for miv-cel in SPS in 1H 2026; Christi Shaw appointed Executive Chair

## Summary
- BLA submission for miv-cel in stiff person syndrome expected in 1H 2026 following positive registrational data.
- Cash, cash equivalents, and marketable securities approx. $279M as of Dec 31, 2025; follow-on offering raised ~$105M.
- First patient enrolled in Phase 3 registrational trial of miv-cel in generalized myasthenia gravis.
- Christi Shaw (former Kite CEO) appointed Executive Chairperson; Ian Clark remains on board.
- Company plans to achieve SPS launch readiness by year-end 2026.

## SEC filing metadata
- accession: 0001193125-26-009810
- form_type: 8-K
- ticker: KYTX
- cik: 0001994702
- company_name: Kyverna Therapeutics, Inc.
- filed_at: 2026-01-12T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1994702/000119312526009810/0001193125-26-009810-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1994702/000119312526009810/kytx-20260108.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-009810
- JSON: https://secwatch.observer/filing/0001193125-26-009810.json
- Plain text: https://secwatch.observer/filing/0001193125-26-009810.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.